Stocks’ Details
 

GetSwift Ltd

Bagged partnerships with global iconic brands: Software-as-a-service solution company, GetSwift Ltd (ASX: GSW) witnessed a stupendous run-up in its stock price with an 84% rise on December 01, 2017. The delivery logistics company inked a global agreement with Amazon and a separate global multi-year partnership with Yum! Brands (operator of brands such as Taco Bell, KFC etc.). While the details of the agreement with Amazon are pending, the stock has been suspended for the time being.
Under the global multi-year partnership with Yum Brands, the latter will get access to GetSwift’s logistics platform. Further, it is expected that over 250 million deliveries annually will benefit from GSW’s platform after implementation. Service in over 20 countries has been slated to be rolled out in two phases with deployment commencing in Middle East and Asia Pac. It will be thus crucial to watch out for the stock movement going forward.
 

Zelda Therapeutics Ltd

Approval of Insomnia Clinical Trial: Zelda Therapeutics Ltd (ASX: ZLD) has announced for receiving the regulatory approval for Australia’s first medicinal cannabis trial for insomnia (which is expected to commence in Q1 2018) from the Therapeutics Goods Administration and the Human Research Ethics Committee. Further, the group has been granted approval for the supply and prescription of Zelda’s medicinal cannabis formulations for the clinical trial by WA Health Department, while the formulations are to be manufactured by European company, Eurofins Sinensis. The clinical trial has been flagged to target a sample population of people with characteristic symptoms of chronic insomnia; and any positive preliminary results from the insomnia clinical trial that are anticipated by Q3 2018, will aid towards commercialisation activities. With plans on track, ZLD stock rose over 14% in last five days and was up 4.2% on December 01, 2017 in early trade prior to ending flat at the close. The group has witnessed a satisfying 12-month’s period and continues its focus on pre-clinical research and human clinical trials. Given more upside to be seen, we put a “Hold” on the stock at the current price of $0.12
 

Magnis Resources Ltd

Sales agreement with fixed pricing: Magnis Resources Ltd (ASX: MNS), which has established itself as a pivotal Consortium Member and owner in developing Lithium-ion battery plants globally, has now secured a Sales Agreement for the supply of flake graphite with European group World Plastik ve Petrokimya Sanayi ve Ticaret, a division of the World Group. The Agreement has been signed for 25,000t p.a. of flake graphite consisting of 15,000t p.a. of Super Jumbo at 97-99% TGC purity and 10,000t p.a. of Jumbo at a purity of 97.5% - 99.5% TGC. MNS can source the graphite from its Nachu project and if required from other mines that produce graphite based on the specifications. The duo has fixed the pricing over the initial 3-year term and first delivery is expected in 2019. This has reinforced the demand scenario for the high purity super jumbo and jumbo flake. Meanwhile, the group also announced about expiry of its unlisted options. We maintain our “Speculative Buy” recommendation at the current price of $0.46
 

Timeline on Developments (Source: Company Reports)

Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.